MSA04
The cell line is not validated yet.
NIMHi028-A
General
Cell Line |
|
| hPSCreg name | NIMHi028-A |
| Cite as: | NIMHi028-A |
| Alternative name(s) |
MSA04
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | No similar lines found. |
| Last update | 24th January 2026 |
| User feedback | |
Provider |
|
| Generator | National Institute of Mental Health and Neurosciences (NIMH) |
| Owner | National Institute of Mental Health and Neurosciences (NIMH) |
| Distributors | |
| Derivation country | India |
External Databases |
|
| BioSamples | SAMEA121031648 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | female |
| Ethnicity | Indian |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Disease associated phenotypes | no phenotypes |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA121031649 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| * Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| * Does consent pertain to a specific research project? | Yes |
| Details on restriction to research project | This work is supported by Pratiksha Trust, titled EMSTAR Project ( Extra-Mural Support for Transformational Aging Brain Research) Scheme of grant number EMSTAR/22/060. Understanding Progression and Natural History of Patients with Atypical Parkinsonism (ATPARK): A Longitudinal Follow-Up Study. |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | Yes |
| How may genetic information associated with the cell line be accessed? | Open Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | National Institute of Mental Health and Neurosciences- Institutional Ethics Committee 44th Meeting |
| Approval number | NIMHANS/44th IEC (BS & NS DIV.)/2023 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | National Institute of Mental Health and Neurosciences- Institutional Ethics Committee 44th Meeting |
| Approval number | NIMHANS/44th IEC (BS & NS DIV.)/2023 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
hIPSC Derivation
General |
|
| Source cell type |
A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.
Synonyms
|
| Source cell origin | |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
Yes |
| Methods used |
PCR
|
| Notes on reprogramming vector detection | Vector gene expression was checked at passage 10 |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Gelatin | |||||||||||||||
| Feeder cells |
mouse embryonic fibroblast |
|||||||||||||||
| Passage method |
Enzymatically
Accutase
|
|||||||||||||||
| CO2 Concentration | 5 % | |||||||||||||||
| Medium |
Other medium:
Base medium: DMEM F12
Main protein source: Knock-out serum replacement Serum concentration: 20 % Supplements
|
|||||||||||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
|||||||||||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
|||||||||||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|
|
|
||
| SOX2 |
Yes |
|
|
|
||
| NANOG |
Yes |
|
|
|
||
| SSEA-4 |
Yes |
|
|
|
||
| TRA 1-60 |
Yes |
|
|
|
Morphology pictures
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.